Tirosina quinasa / adaptadores
Los inhibidores de tirosina quinasa y adaptadores son compuestos que se dirigen a las tirosina quinasas y sus proteínas adaptadoras asociadas, las cuales desempeñan roles cruciales en la señalización celular, el crecimiento y la diferenciación. Estos inhibidores son herramientas esenciales en la investigación del cáncer, ya que muchas tirosina quinasas están involucradas en las vías de señalización que impulsan el crecimiento tumoral y la metástasis. Al inhibir las tirosina quinasas, estos compuestos pueden bloquear cascadas de señalización críticas, ofreciendo potenciales estrategias terapéuticas para varios tipos de cáncer y otras enfermedades que implican una señalización celular anormal. En CymitQuimica, ofrecemos una amplia gama de inhibidores de tirosina quinasa y adaptadores de alta calidad para apoyar su investigación en oncología, biología molecular y desarrollo de terapias dirigidas.
Subcategorías de "Tirosina quinasa / adaptadores"
- ALK(114 productos)
- CSF-1R(42 productos)
- EGFR(572 productos)
- Receptor de efrina(23 productos)
- FLT(91 productos)
- Receptor del factor de crecimiento de fibroblastos (FGFR)(169 productos)
- HER(5 productos)
- Hck(3 productos)
- IGF-1R(91 productos)
- PDGFR(126 productos)
- PYK2(7 productos)
- Src(80 productos)
- Receptor TAM(32 productos)
- Tie-2(21 productos)
- Receptor de Trk(59 productos)
- Tirosina quinasas(26 productos)
- VEGFR(267 productos)
- c-Fms(108 productos)
- c-Kit(102 productos)
- c-Met / HGFR(129 productos)
- c-RET(51 productos)
Mostrar 13 subcategorías más
Se han encontrado 1357 productos de "Tirosina quinasa / adaptadores"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Tyrphostin 51
CAS:<p>Tyrphostin 51 is an effective inhibitor of EGFR kinase.</p>Fórmula:C13H8N4O3Pureza:98%Forma y color:SolidPeso molecular:268.23AMG-Tie2-1
CAS:<p>AMG-Tie2-1 is a Tie2 and VEGFR2 inhibitor with anticancer and antitumor activity for the study of cardiovascular disease and cancer.</p>Fórmula:C25H20F3N5O2Pureza:98.9%Forma y color:SolidPeso molecular:479.45EGFR mutant-IN-2
CAS:<p>EGFR mutant-IN-2 (Compound D51) is an inhibitor of EGFR mutants, specifically targeting EGFR L858R/T790M/C797S and EGFR del19/T790M/C797S mutants with IC50 values of 14 nM and 62 nM, respectively. This compound exhibits favorable pharmacokinetic (PK) parameters, safety properties, in vivo stability, and demonstrates antitumor activity [1].</p>Fórmula:C27H27F3N6O2SForma y color:SolidPeso molecular:556.6EGFR-IN-2
CAS:<p>EGFR-IN-2 is a oral and mutation-selective EGFR inhibito,NSCLC, with high selectivity for resistant single and double mutant T790M.</p>Fórmula:C26H33N9O3SPureza:98.52% - 99.79%Forma y color:SolidPeso molecular:551.66JNJ28871063 hydrochloride
CAS:<p>ErbB receptor family inhibitor</p>Fórmula:C24H28Cl2N6O3Pureza:98%Forma y color:SolidPeso molecular:519.42Spebrutinib besylate
CAS:<p>Spebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a Btk kinase activity inhibitor (IC50<0.5 nM, Kinact/Ki=7.69×104 M-1s-1s).</p>Fórmula:C28H28FN5O6SPureza:98%Forma y color:SolidPeso molecular:581.62Sovleplenib
CAS:<p>Sovleplenib (HMPL-523), oral SYK inhibitor, IC50 25 nM, targets tumors & ITP studies.</p>Fórmula:C24H30N6O3SPureza:99.71%Forma y color:SolidPeso molecular:482.6EMI48
CAS:<p>EMI48, a derivative of EMI1, exhibits increased efficacy against mutant EGFR compared to EMI1. It specifically inhibits EGFR triple mutants [1].</p>Fórmula:C21H20N2O3Forma y color:SolidPeso molecular:348.4EGFR-IN-39
CAS:<p>EGFR-IN-39, an acrylamide, is a potent EGFR inhibitor and antitumor agent targeting NSCLC with low toxicity. See WO2021185348A1 for details.</p>Fórmula:C24H25ClN6O3Forma y color:SolidPeso molecular:480.95EMI56
CAS:<p>EMI56, a derivative of EMI1, exhibits enhanced potency against mutant EGFR compared to EMI1. Additionally, EMI56 effectively inhibits EGFR triple mutants[1].</p>Fórmula:C21H20N2O3Forma y color:SolidPeso molecular:348.4Antiproliferative agent-34
CAS:<p>Antiproliferative Agent-34 (Compound A14), a multitarget kinase inhibitor, demonstrates IC50 values of 177 nM for EGFR L858R/T790M and 1567 nM for EGFR WT.</p>Fórmula:C27H27N7O5Pureza:98%Forma y color:SolidPeso molecular:529.55TG-46
CAS:<p>TG-46 (TG46) inhibits JAK2, FLT3, RET, JAK3 and can be used to study glaucoma.</p>Fórmula:C26H34N6O3SPureza:98.82% - 99.81%Forma y color:SolidPeso molecular:510.65PD 173955-Analog1
CAS:<p>PD 173955-Analog1 is a potent c-Src inhibitor known to have activity against a variety of cancers including colon, lung, head and neck carcinoma.</p>Fórmula:C21H14Cl2N4O3Forma y color:SolidPeso molecular:441.27(E/Z)-AG490
CAS:<p>(E/Z)-AG490 is a racemic mix of (E)- and (Z)-isomers; it inhibits tyrosine kinase, EGFR, Stat-3, and JAK2/3.</p>Fórmula:C17H14N2O3Forma y color:SolidPeso molecular:294.3EGFR-IN-75
<p>EGFR-IN-75 inhibits EGFR WT/T790M; IC50s: 0.28/5.02 μM. It has anticancer and antioxidant effects.</p>Fórmula:C10H6N6S2Forma y color:SolidPeso molecular:274.32EGFR-IN-89
CAS:<p>EGFR-IN-89 (compound 13k) is a fourth-generation inhibitor selectively targeting EGFR mutations, exhibiting potent activity with an IC50 of 10.1 nM against</p>Fórmula:C26H31FN8O2SPureza:98%Forma y color:SolidPeso molecular:538.64EGFR-IN-53
CAS:<p>EGFR-IN-53 (Compound 7) is a potent inhibitor of EGFR (IC50 = 8.264 μM) that exhibits cytotoxic activity against cancer cell lines [1].</p>Fórmula:C14H13N3O2SForma y color:SolidPeso molecular:287.34CAY10717
CAS:<p>CAY10717 inhibits 34/104 kinases at 100 nM, targets EGFR/ABL/B-Raf mutations, kills various cancer cells, and blocks HUVEC growth.</p>Fórmula:C29H25F3N6O3Forma y color:SolidPeso molecular:562.54CHMFL-BTK-01
CAS:<p>CHMFL-BTK-01 is an irreversible inhibitor of BTK (IC50: 7 nM) and also potently inhibits BTK Y223 auto-phosphorylation.</p>Fórmula:C38H41N5O5Pureza:98%Forma y color:SolidPeso molecular:647.76EGFR-IN-64
CAS:<p>EGFR-IN-64 inhibits EGFR with 0.33 μM IC50, showing promising anticancer properties.</p>Fórmula:C20H21N3O3Forma y color:SolidPeso molecular:351.4GSK-2250665A
CAS:<p>GSK-2250665A is an (Itk) inhibitor (pKi 9.2) with selectivity over Aurora B and Btk, inhibiting IFNγ in PBMCs for T-cell signaling studies.</p>Fórmula:C26H29N5OSPureza:98%Forma y color:SolidPeso molecular:459.61EGFR-IN-28
CAS:<p>EGFR-IN-28 is a potent EGFR inhibitor. EGFR-IN-28 has antitumor activity .</p>Fórmula:C31H39BrN10O3SForma y color:SolidPeso molecular:711.68ALK-IN-5
CAS:ALK-IN-5 is a potent, selective, and brain-penetrant inhibitor of anaplastic lymphoma kinase (ALK, IC50: 2.9 nM).Fórmula:C24H25FN6O3Pureza:98%Forma y color:SolidPeso molecular:464.49BAY 2476568
CAS:<p>BAY 2476568 is a selective and potent EGFR inhibitor that acts on both wild-type EGFR (IC50 <0.2 nM) and mutant EGFR (IC50 <0.2 nM).</p>Fórmula:C24H27FN4O4Forma y color:SolidPeso molecular:454.49Lavendustin C6
CAS:<p>Lavendustin C6 is a effective tyrosine kinase inhibitor.</p>Fórmula:C20H25NO5Forma y color:SolidPeso molecular:359.42DDR-TRK-1
CAS:<p>DDR-TRK-1 is a selective discoid domain receptor 1 (DDR1) inhibitor with IC50 value of 9.4 nM. DDR-TRK-1 also inhibits the TRK family.</p>Fórmula:C26H23F3N6OPureza:99.63%Forma y color:SolidPeso molecular:492.5Tyrphostin AG 112
CAS:Tyrphostin AG 112 is an inhibitor of EGFR phosphorylation.Fórmula:C13H8N4OPureza:99.14%Forma y color:SolidPeso molecular:236.23CSF1R-IN-7
CAS:<p>CSF1R-IN-7 is a highly selective CSF-1R inhibitor with good brain penetration for treatment of diseases associated with microglia-mediated neuroinflammation.</p>Fórmula:C22H22N6O3Pureza:99.41% - 99.93%Forma y color:SolidPeso molecular:418.45c-Fms-IN-6
CAS:<p>c-Fms-IN-6 is a potent inhibitor of c-FMS (IC50 ≤10 nM for unphosphorylated c-FMS) and also weakly inhibits unphosphorylated c-KIT and PDGFR (IC50: > 1 μM).</p>Fórmula:C22H25N7O2Pureza:98%Forma y color:SolidPeso molecular:419.48JBJ-04-125-02
CAS:<p>JBJ-04-125-02: Oral EGFR inhibitor, targets EGFRL858R/T790M with 0.26 nM IC50, halts cancer growth, anti-tumor.</p>Fórmula:C29H26FN5O3SPureza:98%Forma y color:SolidPeso molecular:543.61EGFR-IN-68
CAS:<p>EGFR-IN-68, an EGFR inhibitor, has an IC50 of 0.33 μM and shows significant anticancer effects.</p>Fórmula:C24H22N2OForma y color:SolidPeso molecular:354.44DBPR112
CAS:<p>DBPR112: oral furanopyrimidine EGFR inhibitor; IC50: 15 nM (EGFRWT), 48 nM (L858R/T790M); blocks ATP site, strong antitumor effects.</p>Fórmula:C32H31N5O3Pureza:99.25%Forma y color:SolidPeso molecular:533.62AC710 Mesylate
CAS:<p>AC710 Mesylate is a potent PDGFR inhibitor (Kds: 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ).</p>Fórmula:C32H46N6O7SPureza:98%Forma y color:SolidPeso molecular:658.81SSR128129E free acid
CAS:SSR128129E free acid is an orally available and allosteric inhibitor of FGFR(IC50 of 1.9 μM for FGFR1).Fórmula:C18H16N2O4Pureza:98%Forma y color:SolidPeso molecular:324.33ALK2-IN-2
CAS:<p>ALK2-IN-2 is a potent and selective inhibitor of activin receptor-like kinase 2 (ALK2) (IC50: 9 nM), inhibiting ALK2 700-fold more than ALK3.</p>Fórmula:C28H27N5O2SPureza:99.55%Forma y color:SolidPeso molecular:497.61Lanraplenib monosuccinate
CAS:<p>Lanraplenib monosuccinate inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans.</p>Fórmula:C27H31N9O5Pureza:98%Forma y color:SolidPeso molecular:561.59RU-302
CAS:<p>RU-302 is a pan inhibitor of TAM Receptor blocking the interface between the TAM Ig1 ectodomain and the Gas6 Lg domain.</p>Fórmula:C24H24F3N3O2SPureza:99.84%Forma y color:SolidPeso molecular:475.53EAI001
CAS:<p>EAI001 is a potent and selective mutant epidermal growth factor receptor (EGFR) variant inhibitor that inhibits EGFRL858R/T790M with an IC50 value of 24 nM.</p>Fórmula:C19H15N3O2SPureza:>99.99%Forma y color:SolidPeso molecular:349.41Mutated EGFR-IN-2
CAS:Mutated EGFR-IN-2 is an inhibitor of mutant-selective EGFR.Fórmula:C29H35FN8O3Pureza:98%Forma y color:SolidPeso molecular:562.64(E/Z)-CP-724714
CAS:<p>(E/Z)-CP-724714, comprising racemic mixtures of (E)-CP-724714 and (Z)-CP-724714 isomers, is a potent, selective, and orally active inhibitor of ErbB2 (HER2)[1].</p>Fórmula:C27H27N5O3Pureza:98%Forma y color:SolidPeso molecular:469.54Limertinib
CAS:<p>Limertinib (ASK120067) is a EGFR tyrosine kinase inhibitor targeting EGFR T790M, applicable for the study of non-small cell lung cancer.</p>Fórmula:C29H32ClN7O2Pureza:97.44%Forma y color:SolidPeso molecular:546.06AC710
CAS:<p>AC710 is a potent PDGFR inhibitor (Kds: 0.6, 1, 1.57, 1.3, 1 nM for FLT3, KIT, CSF1R, PDGFRα and PDGFRβ).</p>Fórmula:C31H42N6O4Pureza:99.67%Forma y color:SolidPeso molecular:562.7Bezuclastinib
CAS:<p>Bezuclastinib (CGT9486) is a novel, potent and highly selective tyrosine kinase and c-kit D816V inhibitor for the study of advanced mastocytosis.</p>Fórmula:C19H17N5OPureza:99.55%Forma y color:SolidPeso molecular:331.37Gilteritinib hemifumarate
CAS:<p>Gilteritinib hemifumarate (ASP2215 hemifumarate) is a potent ATP-competitive dual FLT3 (IC50: 0.29 nM) and AXL (IC50: 0.73 nM) inhibitor for the treatment of</p>Fórmula:C29H44N8O3C4H4O4Pureza:99.78%Forma y color:SolidPeso molecular:610.75TC-S 7003
CAS:TC-S 7003 (Lck Inhibitor) is a Lck inhibitor with anti-inflammatory activity that inhibits T-cell proliferation and can be used to study arthritis.Fórmula:C31H30N8OPureza:99.74%Forma y color:SolidPeso molecular:530.62EGFR-IN-5
CAS:<p>EGFR-IN-5 inhibits EGFR & mutants; IC50: EGFR 10.4nM, L858R 1.1nM, L858R/T790M 34nM, L858R/T790M/C797S 7.2nM.</p>Fórmula:C31H38FN9OPureza:98.17%Forma y color:SolidPeso molecular:571.69Gefitinib N-oxide
CAS:<p>Gefitinib is an EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells. Gefitinib N-oxide is the N-oxide derivative of Gefitinib.</p>Fórmula:C22H24ClFN4O4Pureza:98%Forma y color:SolidPeso molecular:462.9DS21360717
CAS:<p>DS21360717 is an effective oral tyrosine kinase inhibitor with anticancer activity and IC50 of 0.49 nM.</p>Fórmula:C21H23N7OPureza:98%Forma y color:SolidPeso molecular:389.45EGA
CAS:EGA blocks the entry of a variety of other acid-dependent bacterial toxins and viruses into mammalian cells and can be used to treat infectious diseases.Fórmula:C16H16BrN3OPureza:98% - 99.6%Forma y color:SolidPeso molecular:346.22MS 39
CAS:<p>MS 39, a selective EGFR depressant, degrades mutant receptors in lung cancer lines without affecting wild-type. Effective in vitro and in mice.</p>Fórmula:C55H71ClFN9O7SForma y color:SolidPeso molecular:1056.72
